Obligations incurred through that date and payable for royalties.

No definition available.

Name:	inva_AccruedRoyaltyObligations
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount on net product sales recognized.

+ References

No definition available.

+ Details

Name:	inva_AmountOnNetProductSalesRecognized
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Claim expiration date.

+ References

No definition available.

+ Details

Name:	inva_ClaimExpirationDate
Namespace Prefix:	inva_
Data Type:	xbrli:gYearMonthItemType
Balance Type:	na
Period Type:	duration

- Definition

Clinical development and regulatory milestones amount payable.

+ References

No definition available.

+ Details

Name:	inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Future potential milestone payment receivable.

+ References

No definition available.

+ Details

Name:	inva_FuturePotentialMilestonePayment
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

License revenue recognized.

+ References

No definition available.

+ Details

Name:	inva_LicenseRevenueRecognized
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of maximum royalty based on achievement of annual net product sales thresholds.

+ References

No definition available.

+ Details

Name:	inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds
Namespace Prefix:	inva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of minimum royalty rate.

+ References

No definition available.

+ Details

Name:	inva_PercentageOfMinimumRoyaltyRate
Namespace Prefix:	inva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of reimbursed for direct and certain indirect manufacturing costs.

+ References

No definition available.

+ Details

Name:	inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts
Namespace Prefix:	inva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty payable as a percentage of payments received from sublicensees.

+ References

No definition available.

+ Details

Name:	inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees
Namespace Prefix:	inva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty payable, as a percentage of net sales.

+ References

No definition available.

+ Details

Name:	inva_PercentageOfRoyaltyPayableOnNetSales
Namespace Prefix:	inva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalties payable period after first commercial sale of product.

+ References

No definition available.

+ Details

Name:	inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct
Namespace Prefix:	inva_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Sales milestone payments receivable.

+ References

No definition available.

+ Details

Name:	inva_SalesMilestonePaymentsReceivable
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Subscription agreement one-time milestone payment on commercial sales.

+ References

No definition available.

+ Details

Name:	inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Subscription agreement one-time milestone payment on net sales.

+ References

No definition available.

+ Details

Name:	inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Term of milestone payment for commercial sale.

+ References

No definition available.

+ Details

Name:	inva_TermOfMilestonePaymentForCommercialSale
Namespace Prefix:	inva_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Term of milestone payment for net sales.

+ References

No definition available.

+ Details

Name:	inva_TermOfMilestonePaymentForNetSales
Namespace Prefix:	inva_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

+ Details

Name:	us-gaap_CostOfRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=inva_ZaiLabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_InterimSupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_TechnologyTransferAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_AmendedZaiAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=inva_ResearchAndDevelopmentSupportMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=inva_SulbactamDurlobactamMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=inva_XacduroMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=inva_PaionAgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=inva_CostReimbursementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_CommercialSupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=inva_GeorgeWashingtonUniversityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=inva_GiaprezaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=inva_HarvardUniversityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=inva_ParatekPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=inva_AstrazenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=inva_DurlobactamMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=inva_ZoliflodacinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Arrangements (Additional Information) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Zai Lab \| Interim Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount on net product sales recognized	$ 5,500,000		$ 5,500,000
Zai Lab \| Technology Transfer Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License revenue recognized	3,400,000		3,400,000
Zai Lab \| Amended Zai Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License revenue recognized	800,000		7,300,000
Zai Lab \| Research and Development Support
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future potential milestone payment receivable	91,000,000		91,000,000
Zai Lab \| SUL-DUR
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License revenue recognized			8,000,000
Zai Lab \| XACDURO
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License revenue recognized				$ 3,000,000
PAION AG
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future potential milestone payment receivable	109,500,000		109,500,000
PAION AG \| Cost Reimbursement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	0	$ 1,000,000	0	1,000,000
PAION AG \| Royalty revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	1,200,000		1,300,000
Everest Medicines Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales milestone payments receivable	20,000,000		$ 20,000,000
License revenue recognized				8,000,000
Royalties payable period after first commercial sale of product			10 years
Everest Medicines Limited \| Commercial Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	900,000	900,000	$ 2,600,000	1,600,000
Percentage of reimbursed for direct and certain indirect manufacturing costs			110.00%
Everest Medicines Limited \| Royalty revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	600,000	0	$ 2,300,000	0
George Washington University \| GIAPREZA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales			6.00%
Percentage of royalty on payments received from sublicensees			15.00%
Obligation to pay royalties	1,000,000	$ 500,000	$ 2,500,000	1,700,000
Harvard University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales			5.00%
Percentage of royalty on payments received from sublicensees			20.00%
Cost of license revenue	300,000		$ 1,500,000	$ 1,600,000
Clinical development and regulatory milestones amount payable			$ 15,100,000
Percentage of minimum royalty rate			4.50%
Percentage of maximum royalty based on achievement of annual net product sales thresholds			7.50%
Paratek Pharmaceuticals, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales			2.25%
Claim expiration			2023-10
Astrazeneca \| Durlobactam
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
One-time Milestone Payment on Net Sales			$ 5,000,000
Term of Milestone Payment for Net Sales			3 months
Royalty expense	$ 0		$ 0
Astrazeneca \| Zoliflodacin
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
One-time Milestone Payment on Commercial Sales			$ 10,000,000
Term of Milestone Payment for Commercial Sale			2 years